AbbVie's schizophrenia drug misses main goals of two trials
Portfolio Pulse from
AbbVie's experimental schizophrenia drug did not meet the primary objectives in two mid-stage trials, leading to a significant drop in its share price by over 11% in premarket trading.
November 11, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AbbVie's experimental drug for schizophrenia failed to achieve the main goals in two mid-stage trials, resulting in a significant decline in its stock price.
The failure of the drug in trials is a significant setback for AbbVie, impacting investor confidence and leading to a sharp decline in stock price. The market reaction reflects concerns over the company's pipeline and future revenue potential from this drug.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100